MedTrace Logo

The COLchicine HEART Failure PRESERVED Trial (COLHEART-PRESERVED)

NCT06081049 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2024-02-28

No results posted yet for this study

Summary

The purpose of this study is to investigate the effects of colchicine on heart failure related health status, quality of life, and vascular and cardiac function in patients with heart failure with preserved ejection fraction (HFpEF).

Conditions

Interventions

DRUG

Colchicine

0.5 mg once daily

DRUG

Placebo

Once daily

Sponsors & Collaborators

  • Tor Biering-Sørensen

    lead OTHER

Principal Investigators

  • Camilla Ikast Ottosen, MD · Herlev and Gentofte Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-18
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06081049 on ClinicalTrials.gov